The National Institute for Health and Care Excellence (NICE) has issued positive final draft guidance for a one-off gene therapy which provides a potential cure for certain patients with severe sickle cell disease.
This approval of CASGEVY® (exagamglogene autotemcel) is indicated for individuals 12 years and older who have certain types of severe sickle cell disease.